This article was originally published in The Gray Sheet
Executive SummaryEarnings per share for first quarter 1993 "will likely be in the range of $1.20 to $1.30, compared with $1.51 in the first quarter of 1992," the firm says in a March 15 release. Vaughn Bryson, president and CEO, attributes the decline to lackluster sales of anti-infectives, which "are being affected by a relatively mild flu season and increased competition in the U.S. and Western Europe from other anti-infectives," and to a slowdown in medical devices and diagnostics division sales due to "competitive pressures and the continued production halt at Physio-Control Corporation of products for U.S. shipment." FDA barred Physio-Control from manufacturing in July 1992 due to good manufacturing practice deficiencies and medical device reporting problems ("The Gray Sheet" July 27, 1992. p. 1).
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.